New Bi-Specific Antibody Hitting Two Targets in Myeloma, Dirk Hose, MD and Anja Seckinger, MD, University of Heidelberg

New Bi-Specific Antibody Hitting Two Targets in Myeloma, Dirk Hose, MD and Anja Seckinger, MD, University of Heidelberg
Event Description
Dirk Hose, MD Anja Seckinger, MD Interview Date: May 24, 2017
Many myeloma patients are familiar with monoclonal antibodies, or antibodies that target a specific protein on the surface of myeloma cells. Researchers Dr. Dirk Hose and Dr. Anja Seckinger of the University of Heidelberg in Germany are working on a new bi-specific antibody that joins a powerful myeloma-killing T cell with the target BCMA to selectively target myeloma cells. BCMA is found on many myeloma cells and has become a popular target for a variety of immunotherapies. On a single myeloma cell, over 2,000 BCMA molecules can be present. This is an off-the-shelf approach and impacts myeloma regardless of specific myeloma genetic features. Watch for clinical trials using this new tool in early 2018. Dr. Dirk Hose and Dr. Anja Seckinger on Myeloma Crowd Radio
Thanks to our episode sponsor
Schedule & Agenda
Speakers & Moderators

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org







Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.